Study guide

12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols

WHNP-BC Women's Health Nurse Practitioner Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction: About the WHNP-BC Exam

WHNP-BC Exam Facts, Blueprint & Study Plan

2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening

1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening

3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention

2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites

4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers

3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers

5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility

4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies

6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy

5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion

7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health

6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis

8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care

7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction

9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care

8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy

10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth

9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency

11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions

10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn

12 Chapter 11: Intrapartum Principles & Fetal Surveillance

11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies

13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications

12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs

14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions

13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold

15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders

14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders

16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health

15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis

17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care

16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care

18 Chapter 17: Assessment, Diagnostic Testing & Interpretation

17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities

19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing

18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation

20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities

19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care

12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols

Key Takeaways Explain This Topic AI

Postpartum Hemorrhage (PPH) is defined as cumulative blood loss >=1,000 mL OR blood loss accompanied by signs or symptoms of hypovolemia within 24 hours of birth, regardless of delivery route (vaginal or cesarean); visual estimation notoriously underestimates blood loss by 30% to 50%, mandating standardized quantitative blood loss (QBL) measurement.

Primary (early) PPH occurs within the first 24 hours and is driven by uterine atony in 70% to 80% of cases; secondary (late) PPH occurs between 24 hours and 12 weeks postpartum, most commonly precipitated by retained placental fragments, subinvolution, or endometritis.

The etiologies of PPH are categorized by the "4 Ts": Tone (uterine atony), Tissue (retained placenta, accreta spectrum), Trauma (lacerations, hematomas, uterine inversion/rupture), and Thrombin (consumptive or inherited coagulopathies).

Stepwise uterotonic pharmacotherapy requires strict respect for contraindications: methylergonovine (Methergine) is STRICTLY CONTRAINDICATED in hypertension or preeclampsia due to the risk of severe vasoconstriction and stroke; carboprost tromethamine (Hemabate) is STRICTLY CONTRAINDICATED in active asthma due to potent bronchoconstriction.

Tranexamic acid (TXA, 1 g IV over 10 minutes) must be administered within 3 hours of birth to reduce maternal mortality; refractory bleeding requires intrauterine balloon tamponade (Bakri balloon 300–500 mL), surgical compression sutures (B-Lynch), and activation of a Massive Transfusion Protocol (MTP) with a 1:1:1 ratio of PRBCs, FFP, and platelets.

Last updated: October 2026

Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols

Obstetric hemorrhage remains a leading cause of maternal morbidity and preventable maternal mortality worldwide. Effective management demands prompt recognition, standardized quantitative blood loss (QBL) assessment, and immediate algorithmic intervention across multidisciplinary care teams.

Modern Definition, Staging & Clinical Assessment of PPH

Revising historical bifurcated definitions (500 mL for vaginal delivery vs. 1,000 mL for cesarean), the American College of Obstetricians and Gynecologists (ACOG) and the California Maternal Quality Care Collaborative (CMQCC) establish a unified definition:

Postpartum Hemorrhage (PPH): Cumulative blood loss >=1,000 mL OR blood loss accompanied by signs or symptoms of hypovolemia (e.g., tachycardia, hypotension, tachypnea, oliguria, pallor, diaphoresis, altered sensorium) within 24 hours of birth, regardless of delivery route.

Primary (Early) PPH: Occurs within the first 24 hours following delivery. Overwhelmingly caused by uterine atony (70%–80%).

Secondary (Late) PPH: Occurs between 24 hours and 12 weeks postpartum. Most commonly caused by retained cotyledons or succenturiate lobes, subinvolution of the placental bed, or infection.

Quantitative Blood Loss (QBL): Visual estimation of blood loss (EBL) underestimates actual hemorrhage by 30% to 50%. QBL replaces visual estimation through direct volumetric container measurement and gravimetric dry-weight subtraction (1 g = 1 mL) of blood-soaked sponges and drapes.

Etiologic Classification: The "4 Ts" Framework

Diagnostic evaluation rapidly proceeds through the classic "4 Ts" to identify and correct the underlying source of bleeding:

Etiology ("T") Frequency Pathophysiologic Mechanisms & Clinical Manifestations Specific Risk Factors & Management

Tone (Uterine Atony) 70%–80% Failure of the myometrium to contract firmly around spiral arteries. Uterus is soft, boggy, enlarged, and situated above the umbilicus. Prolonged labor, oxytocin augmentation, chorioamnionitis, multiparity, uterine overdistension (macrosomia, polyhydramnios, multiples). Tx: Fundal massage, uterotonics.

Tissue (Retained Products) 10%–20% Retention of placental cotyledons, succenturiate lobe, or invasive placenta accreta spectrum (accreta, increta, percreta). Previous cesarean delivery, placenta previa, manual removal. Tx: Manual exploration, bedside ultrasound, curettage with banjo curette.

Trauma (Lacerations & Inversion) 15%–20% Lacerations of the cervix, vagina, or perineum; pelvic hematomas; uterine rupture; uterine inversion. Firm, contracted uterus with persistent bright red bleeding. Operative vaginal birth (forceps/vacuum), precipitous birth. Tx: Surgical repair; immediate manual replacement for uterine inversion.

Thrombin (Coagulopathies) <1%–5% Failure of clot formation due to pre-existing coagulopathy (von Willebrand disease, hemophilia) or consumptive coagulopathy (DIC). Placental abruption, severe preeclampsia/HELLP syndrome, amniotic fluid embolism, sepsis. Tx: Fresh frozen plasma, platelets, cryoprecipitate.

Stepwise Uterotonic Pharmacotherapy & Critical Contraindications

Active management of the third stage of labor (AMTSL)—prophylactic oxytocin administration, controlled cord traction, and uterine assessment—is standard for all deliveries. When uterine atony produces active PPH, uterotonics must be administered rapidly in a stepwise fashion:

Uterotonic Agent Standard Dose & Route Mechanism of Action Common Adverse Effects Strict Contraindications & Warnings

Oxytocin (Pitocin) 10–40 units IV in 500–1,000 mL crystalloid; or 10 units IM Stimulates oxytocin G-protein receptors, inducing rhythmic myometrial contraction Water intoxication with large volumes; transient flushing Never administer as rapid undiluted IV bolus (causes severe hypotension, peripheral vasodilation, and cardiac arrest).

Methylergonovine (Methergine) 0.2 mg IM every 2–4 hours (maximum 5 doses); may be given intramyometrial Ergot alkaloid causing sustained, tetanic uterine smooth muscle contraction Nausea, vomiting, headache, acute hypertension STRICTLY CONTRAINDICATED in hypertension, preeclampsia, gestational hypertension, CAD, peripheral vascular disease (risk of stroke and MI).

15-methyl PGF2-alpha (Carboprost / Hemabate) 250 mcg (0.25 mg) deep IM or intramyometrial q15–90 min (max 8 doses / 2 mg) Prostaglandin F2-alpha analog inducing intense myometrial contraction Severe explosive diarrhea, fever, flushing, nausea, chills STRICTLY CONTRAINDICATED in patients with active asthma or reactive airway disease (causes potent bronchospasm).

Misoprostol (Cytotec) 800–1,000 mcg rectally OR 600–800 mcg sublingually/orally (single dose) Synthetic prostaglandin E1 analog stimulating myometrial contraction High-grade pyrexia (temp up to 40°C), severe shivering and rigors Safe in hypertension and asthma. Useful when parenteral access is delayed or refrigerated drugs are unavailable.

Tranexamic Acid (TXA) Protocol

Tranexamic acid is a synthetic lysine analog that competitively inhibits plasminogen activation, stabilizing fibrin clots. Based on the landmark international WOMAN trial (World Maternal Antifibrinolytic Trial):

Dosing & Administration: 1 g IV diluted in 100 mL 0.9% normal saline infused over 10 minutes .

Timing Window: Must be administered within 3 hours of birth . If given >3 hours post-delivery, mortality benefits are lost, and harm may occur.

Repeat Dose: A second 1 g dose may be infused if bleeding persists after 30 minutes or recurs within 24 hours.

TXA does not increase the risk of venous thromboembolism, myocardial infarction, or stroke when administered for obstetric hemorrhage.

Non-Pharmacologic, Tamponade & Surgical Interventions

When pharmacotherapy fails to arrest bleeding, advanced mechanical and surgical modalities must be deployed without delay:

Bimanual Uterine Compression: The clinician inserts a gloved fist into the anterior vaginal fornix, pushing the anterior uterine wall upward, while the other hand compresses the posterior uterine wall through the abdominal wall.

Intrauterine Balloon Tamponade (Bakri Balloon): A silicone balloon catheter is inserted transcervically into the uterine cavity and inflated with 300 to 500 mL of sterile isotonic saline . The balloon exerts hydrostatic counter-pressure exceeding capillary perfusion pressure, tamponading venous sinusoids. A vaginal gauze pack prevents balloon expulsion. The drainage port is monitored for active hemorrhage ("tamponade test"). The balloon remains in place for 12 to 24 hours before gradual deflation.

Uterine Compression Sutures: Laparotomy allows placement of the B-Lynch brace suture (or modified Hayman/Pereira sutures) to exert vertical mechanical compression on the uterine fundus and lower segment.

Surgical Vessel Ligation: Stepwise bilateral uterine artery ligation (O'Leary stitches) and internal iliac (hypogastric) artery ligation reduce pelvic arterial pulse pressure.

Uterine Artery Embolization (UAE): Performed by interventional radiology in hemodynamically stable patients with secondary PPH or persistent oozing.

Emergent Peripartum Hysterectomy: The definitive lifesaving procedure for intractable uterine atony, placenta accreta spectrum, or uterine rupture unresponsive to conservative measures.

Hemodynamic Resuscitation & Massive Transfusion Protocol (MTP)

In Stage 3 hemorrhage (>1,500 mL blood loss, vital sign instability, or suspected DIC):

Establish two large-bore peripheral IV lines (14- or 16-gauge) or central venous access.

Activate Massive Transfusion Protocol (MTP): Transfuse uncrossed O-negative blood until type-specific blood is available. Administer blood components in a balanced 1:1:1 ratio (1 unit Packed Red Blood Cells [PRBCs] : 1 unit Fresh Frozen Plasma [FFP] : 1 unit Platelets) to prevent dilutional coagulopathy.

Fibrinogen Surveillance & Repletion: Maternal fibrinogen levels normally rise to 400–600 mg/dL during pregnancy. A fibrinogen level <200 mg/dL is a critical harbinger of catastrophic hemorrhage and DIC . Replete immediately with cryoprecipitate (10 units raises fibrinogen by ~100 mg/dL) or fibrinogen concentrate.

Prevent the Lethal Triad: Actively prevent hypothermia (fluid warmers, forced-air warming blankets), acidosis (optimize tissue perfusion), and hypocalcemia (replace ionized calcium depleted by citrate preservatives in transfused blood).